SCI Pharmtech, Inc. (4119.TW)
TWD 68.2
(-0.15%)
TWD 68.2
(-0.15%)
| Year | Net Debt | Net Debt Growth |
|---|---|---|
| 2023 | 100.41 Million TWD | -73.47% |
| 2022 | 378.55 Million TWD | 214.69% |
| 2021 | -330.07 Million TWD | 47.64% |
| 2020 | -630.44 Million TWD | -14.51% |
| 2019 | -550.56 Million TWD | -52.43% |
| 2018 | -361.18 Million TWD | -41.16% |
| 2017 | -255.86 Million TWD | 21.44% |
| 2016 | -325.71 Million TWD | 11.51% |
| 2015 | -368.06 Million TWD | -255.97% |
| 2014 | 235.98 Million TWD | 40869.97% |
| 2013 | 576 Thousand TWD | -95.32% |
| 2012 | 12.29 Million TWD | -91.27% |
| 2011 | 140.93 Million TWD | 8.09% |
| 2010 | 130.39 Million TWD | 294.7% |
| 2009 | -66.97 Million TWD | 0.0% |
| Year | Net Debt | Net Debt Growth |
|---|---|---|
| 2024 Q1 | 113.87 Million TWD | 13.41% |
| 2024 Q2 | 281.68 Million TWD | 147.36% |
| 2023 Q4 | 100.41 Million TWD | -86.44% |
| 2023 Q2 | 555.21 Million TWD | -32.96% |
| 2023 Q3 | 740.61 Million TWD | 33.39% |
| 2023 FY | 100.41 Million TWD | -73.47% |
| 2023 Q1 | 828.19 Million TWD | 118.78% |
| 2022 Q4 | 378.55 Million TWD | 1381.57% |
| 2022 Q3 | -29.53 Million TWD | 83.96% |
| 2022 FY | 378.55 Million TWD | 214.69% |
| 2022 Q2 | -184.13 Million TWD | -202.47% |
| 2022 Q1 | 179.7 Million TWD | 154.44% |
| 2021 Q2 | -424.91 Million TWD | 47.5% |
| 2021 Q4 | -330.07 Million TWD | 22.36% |
| 2021 FY | -330.07 Million TWD | 47.64% |
| 2021 Q1 | -809.34 Million TWD | -28.38% |
| 2021 Q3 | -425.12 Million TWD | -0.05% |
| 2020 FY | -630.44 Million TWD | -14.51% |
| 2020 Q3 | -474.9 Million TWD | 38.81% |
| 2020 Q4 | -630.44 Million TWD | -32.75% |
| 2020 Q1 | -653.97 Million TWD | -18.78% |
| 2020 Q2 | -776.05 Million TWD | -18.67% |
| 2019 Q1 | -573.03 Million TWD | -58.66% |
| 2019 FY | -550.56 Million TWD | -52.43% |
| 2019 Q4 | -550.56 Million TWD | -41.57% |
| 2019 Q3 | -388.88 Million TWD | 31.62% |
| 2019 Q2 | -568.74 Million TWD | 0.75% |
| 2018 Q2 | -374.53 Million TWD | -37.51% |
| 2018 Q4 | -361.18 Million TWD | -8.69% |
| 2018 FY | -361.18 Million TWD | -41.16% |
| 2018 Q1 | -272.37 Million TWD | -6.45% |
| 2018 Q3 | -332.28 Million TWD | 11.28% |
| 2017 Q3 | -148.07 Million TWD | 44.8% |
| 2017 FY | -255.86 Million TWD | 21.44% |
| 2017 Q4 | -255.86 Million TWD | -72.8% |
| 2017 Q2 | -268.23 Million TWD | 19.16% |
| 2017 Q1 | -331.82 Million TWD | -1.88% |
| 2016 Q3 | -237.55 Million TWD | 44.03% |
| 2016 Q4 | -325.71 Million TWD | -37.12% |
| 2016 FY | -325.71 Million TWD | 11.51% |
| 2016 Q1 | -351.12 Million TWD | 4.6% |
| 2016 Q2 | -424.42 Million TWD | -20.88% |
| 2015 Q4 | -368.06 Million TWD | -136.82% |
| 2015 Q3 | -155.42 Million TWD | -455.03% |
| 2015 Q2 | 43.77 Million TWD | -80.03% |
| 2015 Q1 | 219.16 Million TWD | -7.13% |
| 2015 FY | -368.06 Million TWD | -255.97% |
| 2014 FY | 235.98 Million TWD | 40869.97% |
| 2014 Q4 | 235.98 Million TWD | -13.18% |
| 2014 Q3 | 271.8 Million TWD | 135.21% |
| 2014 Q2 | 115.55 Million TWD | 707.69% |
| 2014 Q1 | -19.01 Million TWD | -3401.39% |
| 2013 FY | 576 Thousand TWD | -95.32% |
| 2013 Q1 | 537.08 Million TWD | 4267.22% |
| 2013 Q2 | 549.4 Million TWD | 2.29% |
| 2013 Q3 | 56.17 Million TWD | -89.78% |
| 2013 Q4 | 576 Thousand TWD | -98.97% |
| 2012 Q4 | 12.29 Million TWD | -60.11% |
| 2012 Q2 | 55.96 Million TWD | 4.75% |
| 2012 FY | 12.29 Million TWD | -91.27% |
| 2012 Q1 | 53.42 Million TWD | -62.09% |
| 2012 Q3 | 30.83 Million TWD | -44.91% |
| 2011 Q1 | 94.3 Million TWD | -27.68% |
| 2011 Q2 | 67.88 Million TWD | -28.02% |
| 2011 Q3 | 159.01 Million TWD | 134.26% |
| 2011 Q4 | 140.93 Million TWD | -11.37% |
| 2011 FY | 140.93 Million TWD | 8.09% |
| 2010 FY | 130.39 Million TWD | 294.7% |
| 2010 Q4 | 130.39 Million TWD | 0.0% |
| 2009 FY | -66.97 Million TWD | 0.0% |
| Name | Net Debt | Net Debt Difference |
|---|---|---|
| Grape King Bio Ltd | -4.62 Billion TWD | 102.171% |
| Standard Chem & Pharm CO., LTD. | -954.74 Million TWD | 110.518% |
| Maywufa Company Ltd. | 264.18 Million TWD | 61.99% |
| ScinoPharm Taiwan, Ltd. | -3.32 Billion TWD | 103.024% |
| Lotus Pharmaceutical Co., Ltd. | 9.81 Billion TWD | 98.977% |
| LIWANLI Innovation Co., Ltd. | -244.02 Million TWD | 141.151% |
| YungShin Global Holding Corporation | -247.5 Million TWD | 140.572% |
| PhytoHealth Corporation | -34.64 Million TWD | 389.879% |
| Formosa Laboratories, Inc. | 2.53 Billion TWD | 96.044% |
| PharmaEssentia Corporation | -18.46 Billion TWD | 100.544% |
| Bora Pharmaceuticals Co., LTD. | 1.95 Billion TWD | 94.868% |